Latest Administration News

Count Limited reported a robust FY2025 with significant revenue and earnings growth, driven by strategic acquisitions and operational efficiencies. The company’s expansion in wealth management and services segments highlights its evolving market leadership.

Way2VAT has reported a robust first half of FY25, posting a 43% increase in revenue alongside key contract expansions and improved operational efficiency.

ImpediMed Limited has posted a 23% increase in revenue for the 2025 financial year, yet its net loss widened by 17%, with no dividends declared. The company’s financials, audited by Ernst & Young, reveal a complex picture of growth paired with escalating costs.

Smartgroup Corporation Ltd reported a solid first half for 2025 with revenue up 7% and net profit rising 11%, powered by strong novated leasing growth amid shifting electric vehicle policies.

Mineral Resources Limited reported FY25 results highlighting record mining services earnings driven by Onslow Iron's ramp-up, offset by lithium challenges and significant impairments. The company is focused on deleveraging and strengthening governance as it transitions to long-life, low-cost assets.

Mineral Resources Limited posted a $896 million statutory loss for FY25, driven by significant impairments, while Onslow Iron achieved commercial production and governance reforms reshape the board.

Wesfarmers Limited has announced a fully franked ordinary dividend of AUD 1.11 per share for the half-year ending June 2025, offering shareholders multiple currency payment options and a Dividend Reinvestment Plan.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

SIV Capital Limited reported a statutory loss of $112,789 for the year ended June 2025, continuing its operational scale-down with only four active rental contracts. The company remains debt-free with $8.18 million in cash but its ASX securities remain suspended as it evaluates a confidential corporate opportunity.

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.